Transplanted kidneys from living donors survive longer using immunosuppression with Neoral® compared with tacrolimus
Major new study of over 7,000 living donor kidney transplant patients finds type of immunosuppressive therapy makes a difference to long-term outcome
Basel, 3 June 2003 - The long-term chances of survival of a transplanted kidney from a living donor are significantly greater with immunosuppressive therapy based on Neoral® (cyclosporin microemulsion) than with therapy based on tacrolimus, according to a major new study presented today at this year's American Transplant Congress in Washington, DC, USA.1 Immunosuppressive therapy is used to help prevent the body from rejecting a transplanted organ.
Please see full press release under the following link:
